Idecabtagene Vicleucel

CHEMBL4298199 Phase 4 Zugelassen Gene

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This CAR-T cell therapy targets BCMA on multiple myeloma cells, offering treatment for relapsed or refractory disease.

Therapeutische Bereiche

Lymphoma Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

This CAR-T cell therapy targets BCMA on multiple myeloma cells, offering treatment for relapsed or refractory disease.

Yes, Idecabtagene Vicleucel is an approved drug. It has reached clinical phase 4. It is classified as a Gene.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4298199. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Idecabtagene Vicleucel auf PillFYI

Schnelldaten

Synonyme: 1

Externe Links

ChEMBL CHEMBL4298199

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.